Work

EP12.01-70 Anlotinib Combined with Osimertinib Reverses Acquired Osimertinib Resistance in NSCLC by Targeting the c-MET/MYC/AXL Axis

Year: 2023

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2023.09.1286

Authors: T. Lei, T. Xu, N. Zhang, X. Zou, C. Wei, Z. Wang

Institutions: Second Affiliated Hospital of Nanjing Medical University, Nanjing First Hospital, Nanjing Medical University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4388045230

Cites:

Cited by: 1

Related to: 10